Compare LCTX & SPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | SPCE |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 207.3M |
| IPO Year | N/A | N/A |
| Metric | LCTX | SPCE |
|---|---|---|
| Price | $1.68 | $3.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 6 |
| Target Price | $4.25 | ★ $9.22 |
| AVG Volume (30 Days) | 1.3M | ★ 5.5M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,816,000.00 | $1,661,000.00 |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $124.49 | $2,656.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $0.37 | $2.18 |
| 52 Week High | $2.09 | $6.77 |
| Indicator | LCTX | SPCE |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 44.63 |
| Support Level | $1.63 | $2.92 |
| Resistance Level | $1.77 | $4.04 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 28.21 | 26.06 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.